8198 related articles for article (PubMed ID: 24696729)
21. BAP1 and BRAFV600E expression in benign and malignant melanocytic proliferations.
Piris A; Mihm MC; Hoang MP
Hum Pathol; 2015 Feb; 46(2):239-45. PubMed ID: 25479927
[TBL] [Abstract][Full Text] [Related]
22. Expression of Melan-A and Ki-67 in desmoplastic melanoma and desmoplastic nevi.
Kucher C; Zhang PJ; Pasha T; Elenitsas R; Wu H; Ming ME; Elder DE; Xu X
Am J Dermatopathol; 2004 Dec; 26(6):452-7. PubMed ID: 15618925
[TBL] [Abstract][Full Text] [Related]
23. Differentiation of malignant melanoma from benign nevus using a novel genomic microarray with low specimen requirements.
Chandler WM; Rowe LR; Florell SR; Jahromi MS; Schiffman JD; South ST
Arch Pathol Lab Med; 2012 Aug; 136(8):947-55. PubMed ID: 22849744
[TBL] [Abstract][Full Text] [Related]
24. The p16-Ki-67-HMB45 Immunohistochemistry Scoring System is Highly Concordant With the Fluorescent In Situ Hybridization Test to Differentiate Between Melanocytic Nevi and Melanomas.
Uguen A; Uguen M; Guibourg B; Talagas M; Marcorelles P; De Braekeleer M
Appl Immunohistochem Mol Morphol; 2018 Jul; 26(6):361-367. PubMed ID: 27490764
[TBL] [Abstract][Full Text] [Related]
25. PNL2: A Useful Adjunct Biomarker to HMB45 in the Diagnosis of Uterine Perivascular Epithelioid Cell Tumor (PEComa).
Valencia-Guerrero A; Pinto A; Anderson WJ; Trevisan G; Nucci MR; Hirsch MS
Int J Gynecol Pathol; 2020 Nov; 39(6):529-536. PubMed ID: 31851063
[TBL] [Abstract][Full Text] [Related]
26. Tissue microarray analysis of ezrin, KBA.62, CD166, nestin, and p-Akt in melanoma versus banal and atypical nevi, and nonmelanocytic lesions.
Shanesmith RP; Smart C; Cassarino DS
Am J Dermatopathol; 2011 Oct; 33(7):663-8. PubMed ID: 21915031
[TBL] [Abstract][Full Text] [Related]
27. p16ink4a expression in benign and malignant melanocytic conjunctival lesions.
Zoroquiain P; Fernandes BF; González S; Novais GN; Schalper KA; Burnier MN
Int J Surg Pathol; 2012 Jun; 20(3):240-5. PubMed ID: 22287653
[TBL] [Abstract][Full Text] [Related]
28. Expression of activated Akt in benign nevi, Spitz nevi and melanomas.
Kantrow SM; Boyd AS; Ellis DL; Nanney LB; Richmond A; Shyr Y; Robbins JB
J Cutan Pathol; 2007 Aug; 34(8):593-6. PubMed ID: 17640227
[TBL] [Abstract][Full Text] [Related]
29. Fascin expression in melanocytic lesions of the skin.
YILDIZ L; KEFELI M; AYDIN O; KANDEMIR B
Eur J Dermatol; 2009; 19(5):445-50. PubMed ID: 19527987
[TBL] [Abstract][Full Text] [Related]
30. WT1 and Bcl2 expression in melanocytic lesions of the conjunctiva: an immunohistochemical study of 123 cases.
Furusato E; Hidayat AA; Man YG; Auerbach A; Furusato B; Rushing EJ
Arch Ophthalmol; 2009 Aug; 127(8):964-9. PubMed ID: 19667332
[TBL] [Abstract][Full Text] [Related]
31. Expression of the B-cell proliferation marker MUM1 by melanocytic lesions and comparison with S100, gp100 (HMB45), and MelanA.
Sundram U; Harvell JD; Rouse RV; Natkunam Y
Mod Pathol; 2003 Aug; 16(8):802-10. PubMed ID: 12920225
[TBL] [Abstract][Full Text] [Related]
32. Nuclear to non-nuclear Pmel17/gp100 expression (HMB45 staining) as a discriminator between benign and malignant melanocytic lesions.
Rothberg BE; Moeder CB; Kluger H; Halaban R; Elder DE; Murphy GF; Lazar A; Prieto V; Duncan LM; Rimm DL
Mod Pathol; 2008 Sep; 21(9):1121-9. PubMed ID: 18552823
[TBL] [Abstract][Full Text] [Related]
33. A Diagnostic Algorithm Combining Immunohistochemistry and Molecular Cytogenetics to Diagnose Challenging Melanocytic Tumors.
Redon S; Guibourg B; Talagas M; Marcorelles P; Uguen A
Appl Immunohistochem Mol Morphol; 2018; 26(10):714-720. PubMed ID: 28362709
[TBL] [Abstract][Full Text] [Related]
34. Immunoprofile of MITF, tyrosinase, melan-A, and MAGE-1 in HMB45-negative melanomas.
Xu X; Chu AY; Pasha TL; Elder DE; Zhang PJ
Am J Surg Pathol; 2002 Jan; 26(1):82-7. PubMed ID: 11756773
[TBL] [Abstract][Full Text] [Related]
35. Melanocytic Nevi with Site-related Atypia: A Case Series and Characterization of their Immunohistochemical Profile.
Hussein MRA
Actas Dermosifiliogr (Engl Ed); 2021 Mar; 112(3):242-249. PubMed ID: 33232704
[TBL] [Abstract][Full Text] [Related]
36. Rate of Immunohistochemistry Utilization in the Diagnosis of Cutaneous Melanocytic Lesions.
Chen TC; Hitchcock MG
Am J Dermatopathol; 2021 Dec; 43(12):e146-e148. PubMed ID: 33795556
[TBL] [Abstract][Full Text] [Related]
37. Vascular endothelial growth factor expression in malignant melanoma: prognostic versus diagnostic usefulness.
Bayer-Garner IB; Hough AJ; Smoller BR
Mod Pathol; 1999 Aug; 12(8):770-4. PubMed ID: 10463478
[TBL] [Abstract][Full Text] [Related]
38. Conjunctival nevi and melanoma: multiparametric immunohistochemical analysis, including p16, SOX10, HMB45, and Ki-67.
Milman T; Zhang Q; Ang S; Elder D; Ida CM; Salomao DR; Lally SE; Shields JA; Hamershock RA; Sioufi K; Shields CL; Eagle RC
Hum Pathol; 2020 Sep; 103():107-119. PubMed ID: 32707054
[TBL] [Abstract][Full Text] [Related]
39. S100A6 protein expression is different in Spitz nevi and melanomas.
Ribé A; McNutt NS
Mod Pathol; 2003 May; 16(5):505-11. PubMed ID: 12748257
[TBL] [Abstract][Full Text] [Related]
40. A multi-marker assay to distinguish malignant melanomas from benign nevi.
Kashani-Sabet M; Rangel J; Torabian S; Nosrati M; Simko J; Jablons DM; Moore DH; Haqq C; Miller JR; Sagebiel RW
Proc Natl Acad Sci U S A; 2009 Apr; 106(15):6268-72. PubMed ID: 19332774
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]